Article
Author: Soede, Camillia ; Kapoor, Rajiv ; Caenepeel, Sean ; Madsen, Mads ; Flagstad, Thomas ; Moretti, Loris ; Xie, Fang ; Lo, Mei-Chu ; Andersson, Jan ; Moriguchi, Jodi ; Mardirossian, Narbe ; Peng, Chi-Chi ; Kuropatnicka, Aleksandra ; Pettus, Liping ; Hughes, Paul ; Li, Kexue ; Sarvary, Ian ; Jacso, Tomas ; Franch, Thomas ; Nadali, Anna ; Ghimire-Rijal, Sudipa ; Peiró Cadahía, Jorge ; Husemoen, Gitte ; Pii, David ; Slemmons, Katherine K. ; Vestergaard, Mikkel ; Cowland, Sanne ; Mukund, Susmith ; Ryborg, So̷ren ; Liu, Qingyian ; Gouliaev, Alex ; Kronborg, Titi ; Allen, Jennifer R. ; Tamayo, Nuria ; Glad, Sanne ; Liu, Siyuan ; Yang, Yajing ; Belmontes, Brian ; Wang, Paul ; Nielsen, So̷ren ; Madoux, Franck ; Ngo, Rachel ; Bourbeau, Matthew
Inhibition of the methyltransferase enzyme PRMT5 by MTA accumulation is a vulnerability of MTAP-deleted cancers. Herein, we report the discovery and optimization of a quinolin-2-amine DEL hit that cooperatively binds PRMT5:MEP50 and MTA to generate a catalytically inhibited ternary complex. X-ray crystallography confirms quinolin-2-amine binding of PRMT5 glutamate-444, while simultaneously exhibiting a hydrophobic interaction with MTA. Lead optimization produced AM-9747, which selectively inhibits PRMT5-directed symmetric dimethylation of arginine residues of proteins, leading to a potent reduction of cell viability in MTAP-del cells compared to MTAP-WT cells. Once-daily oral dosing of AM-9747 in mouse xenografts is well tolerated, displaying a robust and dose-dependent inhibition of symmetric dimethylation of arginine in MTAP-del tumor-xenografts and significant concomitant tumor growth inhibition without any significant effect on MTAP-WT tumor xenografts.